RECURRENT ENDOMETRIAL CARCINOMA
Clinical trials for RECURRENT ENDOMETRIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced (stage III or IV) or recurrent endometrial cancer. About 800 participants received either the combo or chemo alone. The …
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase II trial tests whether adding ribociclib to a standard two-drug regimen (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. About 90 participants will be randomly assigned to receive either the two-drug or three-drug combin…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo targets returned ovarian and uterine cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combina…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New Triple-Drug cocktail shows promise for Tough-to-Treat recurrent cancers
Disease control OngoingThis study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE2 • Sponsor: Floor Backes, MD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Virus therapy targets Hard-to-Treat endometrial cancer
Disease control OngoingThis early-stage trial tests a specially modified virus (VSV-hIFNbeta-NIS) given through an IV to people with advanced or recurrent endometrial cancer. The virus is designed to attack cancer cells while leaving healthy cells alone, and it includes a tracer to see where it goes in…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC